W. Sandborn

Genetics · 2000–2020

A researcher in the Science corpus: 53 papers; trusts 6 researchers and is trusted by 11 researchers here, as inferred from the citation graph.

Subfields

Whom W. Sandborn trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. S. Hanauer
  2. B. Feagan
  3. P. Rutgeerts
  4. J. Colombel
  5. Stefan Schreiber
  6. E. Loftus
  7. G. Lichtenstein
  8. Daniel C. Baumgart
  9. Bruce E. Sands

Who trusts W. Sandborn overall

  1. Markus F. Neurath
  2. Stefan Schreiber
  3. G. Lichtenstein
  4. Daniel C. Baumgart
  5. B. Feagan
  6. J. Colombel
  7. Nora Koutruba
  8. S. Hanauer
  9. Bruce E. Sands
  10. J. Langhorst

Papers from W. Sandborn's perspective

Ordered by how strongly the researchers W. Sandborn trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. (Gastroenterology)
  2. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. (Gastroenterology)
  3. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (Gastroenterology)
  4. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee (American Journal of Gastroenterology)
  5. Placebo Effects: Biological, Clinical and Ethical Advances (The Lancet)
  6. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. (Clinical Gastroenterology and Hepatology)
  7. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (Gastroenterology)
  8. A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 (Inflammatory Bowel Diseases)
  9. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (Canadian journal of gastroenterology = Journal canadien de gastroenterologie)
  10. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. (The Lancet)

Their papers